Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
← catalyst calendarNCT07632898 · readout in 1,411 d
Sponsored by Inhibikase Therapeutics (industry) · IKT — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
484estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-23 | estimated | When the study began enrolling |
| Primary completion | 2030-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Arterial Hypertension (PAH)
Intervention
- Drug: IKT-001
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs of special interest
measured From baseline to end of study (up to 2 years or availability of commercial product)
Permalink · IKT's whole pipeline · Catalyst calendar · Every registered study · What changed